Cyclerion Therapeutics 

Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier. It is presently in Phase IIa clinical assessments for managing mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), as well as Alzheimer's disease with vascular involvement. Concurrently, CY6463 is undergoing Phase 1 trials for treating schizophrenia in adult populations. The company's research portfolio also features other promising candidates: Praliciguat, an orally administered systemic sGC stimulator, is in Phase II studies targeting resistant hypertension and diabetic nephropathy. Olinciguat, another sGC stimulator designed for oral intake with a vascular focus, is progressing through Phase II trials for sickle cell disease. Moreover, CY3018 is under development to address a range of CNS ailments. Cyclerion holds a licensing agreement with Akebia Therapeutics, Inc., covering the entire lifecycle from development and manufacturing to medical affairs and commercialization for certain pharmaceutical compounds and related products. The company was founded in 2018 and has its principal place of business in Cambridge, Massachusetts.